A break fee in a merger-gone-south can be deducted as an ordinary expense, the U.S. Tax Court held today, finding for biopharmaceutical giant AbbVie and rejecting the IRS’s argument that AbbVie must treat the fee as a capital...more
The IRS workforce continues to shrink, with deferred resignations of hundreds of IRS Appeals personnel....more
In Actavis v. U.S., a case at the intersection of tax law and patent law, the Federal Circuit held that generic drug companies’ Hatch-Waxman litigation expenses are “ordinary and necessary business expenses” and can be...more
3/25/2025
/ Abbreviated New Drug Application (ANDA) ,
Actavis Inc. ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Internal Revenue Code (IRC) ,
IRS ,
Litigation Fees & Costs ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Tax Court ,
Tax Deductions ,
Tax Planning